Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Total Current Assets
All assets expected to be converted to cash or used up within one year.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Total Current Assets · Q4 FY2025 · quarter ended Dec 2025
Total current assets rises 63.2% from a year ago
Total current assets stood at $30.24M at the end of Q4 FY2025, up 63.2% from a year earlier. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Total current assets amounted to 100.0% of total assets at the end of Q4 FY2025, up 2.0 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +63.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 30.24M USD
- Year-over-year change
- +63.2%
- 4-year CAGR
- +57.5%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.24M | +63.2% |
| FY2024 | 2024-12-31 | 18.53M | +17.7% |
| FY2023 | 2023-12-31 | 15.75M | +13.0% |
| FY2022 | 2022-12-31 | 13.94M | +183.6% |
| FY2021 | 2021-12-31 | 4.92M | — |
Total Current Assets vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +63.2% is the 3rd highest of 10, against a peer median of -0.3%.
- Total current assets amounts to 100.0% of total assets for NNNN, versus a peer median of 59.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.77B USD | +10.7% | +1.6% | 28.6% | |
| Mar 2026 | $510.87M USD | +67.2% | -0.0% | 96.1% | |
| Mar 2026 | CA$419.53M CAD | -0.3% | -3.5% | 31.9% | |
| Mar 2026 | $325M USD | -7.8% | -17.1% | 30.9% | |
| Dec 2025 | $320.15M USD | — | — | 95.5% | |
| Mar 2026 | $234.03M USD | +59.7% | +27.5% | 46.4% | |
| Feb 2026 | $155.55M USD | -9.7% | +5.5% | 59.7% | |
| Mar 2026 | $124.54M USD | -54.8% | -13.8% | 96.6% | |
| Mar 2026 | $110.5M USD | -11.0% | -10.0% | 81.1% | |
| Mar 2026 | $54.88M USD | +126.6% | +7.5% | 58.7% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $30.24M USD | +63.2% | +29.4% | 100.0% |
| Peer median (excluding NNNN) | — | -0.3% | -0.0% | 59.2% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.